STOCKWATCH: The strategic review – a prelude to value destruction
This article was originally published in Scrip
The news that a company is conducting a strategic review has grandiose implications of high-flying investment bankers, consultants and board members scouring the world and the management literature for examples of how successful companies have moved from strength to strength, and then how those lesions can be applied to the company in question.
You may also be interested in...
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.
While big tech is suffering from a return to normality after the pandemic, big pharma always had a recovery in its base business to return to. But after the third-quarter earnings season, it seems both base and pandemic pharmaceutical businesses are still co-existing for now.